Additional Information
Market: NYSE
Sector: Medical
EPIC: BAX
Latest Price: 73.16  (1.23% Ascending)
52-week High: 77.00
52-week Low: 66.49
Market Cap: 39,651.10M
1 year chart
1 day chart
Baxter International
www.baxter.com

Baxter International is a global medical products and services company. Via its principal operating subsidiary, Baxter Healthcare Corporation, the company delivers products, which are sold in over 100 countries and are used by health-care professionals and their patients in the treatment of complex medical conditions, including haemophilia, immune disorders, kidney disease, cancer and trauma.

Baxter buys Sweden's Gambro for $4 bln

4th Dec 2012, 9:22 am by Joyanta Acharjee
Baxter has considered doing a deal with Gambro for years. Baxter has considered doing a deal with Gambro for years.

Drug and medical device maker Baxter International (NYSE:BAX) said Tuesday it plans to buy privately-held Swedish company Gambro for about $2.76 billion to broaden its dialysis product portfolio.

Baxter will pay for the deal with a combination of debt and cash. It expects the acquisition to close in the first half of next year. In total, the deal is worth about $4 billion, including debt.

Gambro makes dialysis products for patients with acute or chronic kidney disease, and Baxter said it had sales of about $1.6 billion last year.

Baxter has considered doing a deal with Gambro for years. Gambro is considerably smaller than Baxter, which has a market value of some $36 billion and had sales last year of $13.9 billion. The company also had more than $3 billion of cash as of September.

Baxter said dialysis treatment rates are rising by more than 5 per cent annually, partly due to growing rates of diabetes and high blood pressure. More than 2 million people globally are on some form of dialysis.

Dialysis involves removing blood from a patient, running it through a machine that cleans out impurities and then returning it to the patient's body. Baxter's medical device division makes products for kidney dialysis and intravenous administration sets to deliver medicines and fluids to patients.

Baxter also has a bioscience division that makes vaccines and high-tech treatments for hemophilia and other bleeding disorders, burns and shock, immune deficiencies and other blood-related conditions.

Baxter makes medical devices, pharmaceuticals and biotechnology products, focusing on areas including hemophilia, immune disorders and infectious diseases. 

It divides its operations between a bioscience division, which generated just under half of company sales last year, and a medical-products division, which produced the rest.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here